Rapid Micro Biosystems, Inc. today announced that it is set to join the Russell 2000®, Russell 3000® and Russell Microcap® indexes, effective after the U.S. market opens on September 20, 2021
LOWELL, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems (Nasdaq: RPID), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it is set to join the Russell 2000®, Russell 3000® and Russell Microcap® indexes, effective after the U.S. market opens on September 20, 2021, according to a preliminary list of quarterly IPO additions posted by FTSE Russell to their website late last month.
Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
“We are pleased that we will soon be included in three different Russell indices following the successful closing of our IPO in July,” said Rob Spignesi, President and CEO. “This will increase the awareness of our stock within the investment community and help us to highlight the strength of our business model as we continue towards our goal of transforming the standard for safe and efficient microbial quality control in pharmaceutical manufacturing globally.”
For more information on the Russell 2000®, Russell 3000® and Russell Microcap® indexes, go to the FTSE Russell website.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.
About FTSE Russell
FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com
Rapid Micro Contacts: Investor Contact: David Deuchler Gilmartin Group LLC investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
